Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,619.00
Bid: 1,618.50
Ask: 1,619.00
Change: -147.50 (-8.35%)
Spread: 0.50 (0.031%)
Open: 1,616.50
High: 1,621.00
Low: 1,589.50
Prev. Close: 1,766.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Back to School: "7% downside to European equities"

Thu, 10th Sep 2020 12:21

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni and Stefano
Rebaudo (stefano.rebaudo@thomsonreuters.com) in Milan.

BACK TO SCHOOL: "7% DOWNSIDE TO EUROPEAN EQUITIES" (1110 GMT)

European stocks have risen 38% from March lows and now might be the time to lock in some
profits, at least according to UBS.

"Having been bullish back in March, we now see c.7% downside to European equities,"
strategist at the Swiss bank say.

Their base-case scenario is 340 points for the STOXX 600 at end-2020, based on
expectations earnings are going to fall 33% this year before bouncing 25% in 2021.

Of course things could pan out differently.

* Upside scenario (+13%): multiple expansion continues, positive news on a vaccine, "TINA"
there
is no alternative, US investors return to Europe, a new U.S. fiscal package

* Downside scenario (-20%): rolling regional/national lockdowns, Government support schemes
fade,
U.S. elections, increased US/China trade tensions, a "no deal" Brexit

(Danilo Masoni)

*****

DUNELM'S SPOOKY "SEVERE BUT PLAUSIBLE DOWNSIDE" SCENARIO (1039 GMT)

There's been quite a bit of disappointment to see the shares in British home furnishing
retailer Dunelm retreat this morning despite the encouraging sales achieved in the face
of the coronavirus pandemic.

Much of today's negative price action seems to be blamed on profit taking and on the
decision of Dunelm, a clear lockdown winner, to play it safe and to keep some cash for the
possible rainy days ahead.

"Despite strong current trading, a still uncertain outlook and 'prudent financial approach'
means the Board has chosen not to declare a final dividend for FY20 and management has not
issued FY21 PBT guidance", UBS analysts noted.

But another important part of Dunelm's earnings which might have spooked investors is the
retailer's assessment of what could go wrong.

"There is a fear stalking some companies", commented Neil Wilson at Markets.com, noting the
group's warning of a "severe but plausible" downside scenario which involves lockdowns over
Christmas.

Here's how Dunelm describes in its press release what could happen in a few months to its
business, but by extension to most European retailers:

"The 'severe but plausible downside' scenario is very conservative in assuming a further
national lockdown for ten weeks where our stores are no longer in the 'permitted' status and
where we are unable to offer our Click & Collect service.

We have also assumed that this national lockdown occurs in our peak Christmas and Winter
Sale trading period, with all of the Group's stores being required to shut for ten weeks in the
event of a second Covid-19 outbreak, on top of the downturn in the economy that is already
included in the central case, including potential Brexit-related disruption."

Yikes and merry Xmas everybody!

On a more positive note for Dunelm shareholders, the company "has been a clear relative
winner in the sector through the crisis, with possibly some lasting benefits from strong
customer acquisition," JP Morgan analysts believe.

Anyhow, here's how Dunelm has outperformed the FTSE 250 and how it's comparing with other
top retailers so far in 2020:

(Julien Ponthus)

*****

WHAT ABOUT A PE RATIO OF 100? (0955 GMT)

These days more than ever stock valuations seem to be a matter of how much cash is lying on
the sidelines as central banks are in a "whatever it takes" mood to pour liquidity in order to
avoid the adverse impact of the virus.

Jeroen Blokland, portfolio manager at Robeco, crunched some numbers to measure the
relationship between excess liquidity -- as the difference between money supply and nominal GDP
growth -- and the PE of the S&P 500 stocks.

He concludes that the PE ratio should be at a whooping 100, from around 28 these days.

"Obviously, this is not going to happen, also because nominal GDP growth is expected to
bounce back sharply," he says in a research note. "But it does point out that from a liquidity
perspective, valuation looks far from stretched".

The idea behind this is that if there is more money than needed for economic growth, excess
liquidity will find its way into the stock market.

(Stefano Rebaudo)

*****

BREXIT TURBO-CHARGES UK RISK PREMIA (0850 GMT)

Risk premia on UK assets are rising and will continue to do so as investors fear a messy
divorce with the European Union when Britain finally disentangles at the end of the year.

The European Union could take legal action under its divorce treaty with Britain if today’s
emergency talks do not reassure Brussels sufficiently that a proposed new British law will not
break previously agreed commitments.

An ABN Amro research note recalls that, inside the bond bank index, NatWest Group
over the last seven days staged "the largest underperformance, with their bail-in senior bonds
moving over 30bps wider."

Other names, such as Lloyds and Barclays have only performed a few basis
points better while HSBC, Santander UK and Standard Chartered have suffered a
20 basis points hit.

ABN Amro analysts anticipate that the Brexit negotiations will continue to produce negative
headlines with little achieved in the forthcoming weeks. "UK risks premiums are likely to stay
elevated for the remainder of this year," they say.

The bank index is at 79 basis points (bps) above the swap, roughly 29 bps wider than before
the coronavirus crisis and 158 bps tighter than the pandemic highs experienced in March.

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: EUROPE WAVERS BEFORE THE ECB (0725 GMT)

We're off to an uncertain start in Europe this morning with investors awaiting for the ECB
to provide fresh direction with hints of more stimulus to soften the strength of the euro
against the dollar.

Major regional benchmarks were down slightly, following mild initial gains. The STOXX 600 is
last down 0.15%.

Pandemic-hit travel and leisure stocks are up 0.7% with British Airways owner IAG
up over 2% after launching a fully underwritten 2.7 billion euros capital increase to beef up
its balance sheet.

Games Workshop is up an outstanding 18% after saying trading in the three months to
end August topped its expectations.

UK listed housebuilders are doing well after an upbeat RICS survey showed that the
post-lockdown surge in the housing market intensified in August with prices hitting a 4-year
high. Taylor Wimpey and Barratt are both up more than 2%.

Italy's Nexi is up 5% after a report said the payment firms and SIA are close to
clearing a major hurdle to a potential merger.

Weaker oil and basic material stocks weighed. Tech was lower too.

(Danilo Masoni)

*****

ON OUR RADAR: EURO, IAG CAP RISE AND DEALMAKING (0644 GMT)

As we said the European Central Bank's policy meeting and any signals from the central bank
about future easing measures will be the key highlight for investors today.

The euro and bond markets are likely to be most sensitive to ECB news, but we'll be
keeping an eye on stocks too, especially on rate-sensitive sectors like banks.

Besides that, on the corporate front, it doesn't look there is any earth shattering news out
there so far.

This will be the first full session for investors to digest LVMH's decision to
walk away from its planned $16 billion takeover of Tiffany. LVMH was little changed on
the news yesterday.

Airlines, which have been heavily hit by travel restrictions adopted to fight the COVID
pandemic, continue to be under pressure. British Airways owner IAG launched a heavily
discounted 2.7 billion euros capital increase to beef up its finances. The good news here is
that it's fully underwritten.

GlaxoSmithKline said the U.S health regulator approved its lung disease drug Trelegy
Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be
prescribed for uncontrolled asthma in the country.

In M&A, Equinor raised $1.1 billion by selling stakes in offshore wind power
development projects to BP, while in Italy, the government said it's ready to use its
vetting "golden" powers to ensure the Milan exchange is not sold to an unacceptable bidder.

Meanwhile in France, utility Suez reiterated its opposition to Veolia’s
offer for Engie's stake in Suez, saying it undervalued Suez.

Among smaller companies, share placement are expected to put under pressure Ferroamp
, Carasent, and Kojamo.

In earnings news, an upbeat outlook from Akzo Nobel could lift its shares, while Dixons
reported a 56% drop mobile phone in the 17 weeks to end-August.

(Danilo Masoni)

*****

MORNING CALL: IT'S ECB DAY (0530 GMT)

Regardless of whether it's going to have any big impact on markets today the focus is
squarely on the European Central Bank's policy meeting.

The consensus is that rates will remain unchanged although investors expect signals from the
central bank which could possibly weaken the euro.

On the background are still worries over rising Brexit risks and possible further turbulence
in tech stocks, and it may be little surprise that following yesterday's rebound in Europe and
the U.S., futures are giving mixed signals at the moment.

The Euro STOXX 500 futures are up 0.3%, FTSE 100 futures are down 0.3% and Wall Street
futures are moving flat to slightly higher.

(Danilo Masoni)

*****

More News
24 Jul 2023 07:07

GSK's ViiV gets Europe nod for HIV prophylaxis

(Sharecast News) - Pharmaceuticals giant GSK announced on Monday that its majority-owned HIV specialist subsidiary ViiV Healthcare has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorisation for 'cabotegravir' long-acting (LA) injectable and tablets for HIV prevention.

Read more
22 Jul 2023 18:32

Bavarian Nordic ends RSV vaccine programme after poor trial results

July 22 (Reuters) - Denmark-based Bavarian Nordic said on Saturday it was ending its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventing lower respiratory tract disease.

Read more
14 Jul 2023 09:13

LONDON BROKER RATINGS: HSBC says 'buy' AstraZeneca but 'reduce' GSK

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
14 Jul 2023 07:56

LONDON BRIEFING: Burberry shines in China; ITV-All3Media deal unlikely

(Alliance News) - Stocks in London are expected to slip into the red at Friday's open, in a tepid conclusion to what has been a largely positive week for global equities, as the market prices in a lower peak for US interest rates.

Read more
13 Jul 2023 16:13

Sensodyne toothpaste-maker Haleon planning job cuts - The Guardian

July 13 (Reuters) - Haleon, the world's biggest standalone consumer health business, is planning to cut hundreds of roles in the UK and worldwide, the Guardian reported on Thursday.

Read more
10 Jul 2023 09:27

LONDON BROKER RATINGS: HSBC downgrades commercial property stocks

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
6 Jul 2023 15:46

UK dividends calendar - next 7 days

Friday 7 July 
Anglo-Eastern Plantations PLCdividend payment date
Associated British Foods PLCdividend payment date
Blackrock Frontiers Investment Trust PLCdividend payment date
Crystal Amber Fund Ltddividend payment date
Forterra PLCdividend payment date
Hill & Smith PLCdividend payment date
JPMorgan Global Growth & Income PLCdividend payment date
LXi REIT PLCdividend payment date
Restore PLCdividend payment date
S&U PLCdividend payment date
Titon Holdings PLCdividend payment date
Victorian Plumbing Group PLCdividend payment date
Warehouse REIT PLCdividend payment date
Whitbread PLCdividend payment date
WPP PLCdividend payment date
Monday 10 July 
Capital Gearing Trust PLCdividend payment date
Great Portland Estates PLCdividend payment date
Tuesday 11 July 
Emis Group PLCdividend payment date
Pets at Home Group PLCdividend payment date
Wednesday 12 July 
Assura PLCdividend payment date
LondonMetric Property PLCdividend payment date
M&C Saatchi PLCdividend payment date
Pharos Energy PLCdividend payment date
Renew Holdings PLCdividend payment date
Thursday 13 July 
BlackRock Latin American Investment Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Caffyns PLCex-dividend payment date
CMC Markets PLCex-dividend payment date
FirstGroup PLCex-dividend payment date
GSK PLCdividend payment date
Halma PLCex-dividend payment date
Invesco Bond Income Plus Ltdex-dividend payment date
JPMorgan Japan Small Cap Growth & Income PLCex-dividend payment date
Record PLCex-dividend payment date
Schroder UK Mid Cap Fund PLCex-dividend payment date
Shoe Zone PLCex-dividend payment date
Sirius Real Estate Ltdex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
Triad Group PLCex-dividend payment date
Wincanton PLCex-dividend payment date
XP Power Ltddividend payment date
Young & Co's Brewery PLCdividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
5 Jul 2023 09:34

LONDON BROKER RATINGS: UBS likes Pearson; Liberum cuts Naked Wine

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
4 Jul 2023 10:18

PRESS: Advil owner Haleon to explore sale of nicotine gum business

(Alliance News) - Haleon PLC is exploring a potential divestment of some smoking cessation products, including the Nicotinell brand of nicotine gum, patches and lozenges, according to a Bloomberg report on Tuesday.

Read more
30 Jun 2023 22:38

First trial over Zantac cancer claims set for November

June 30 (Reuters) - The first U.S. trial over claims that discontinued heartburn drug Zantac causes cancer is now expected to take place in California state court on Nov. 13, a lawyer for plaintiffs in the litigation said Friday.

Read more
29 Jun 2023 06:30

Sanofi says it's back to the drawing board on mRNA flu vaccines

June 29 (Reuters) - Sanofi said that trials show the currently available mRNA technology behind the most successful COVID-19 shots will not be effective against influenza and it is already working on a next generation of shots.

Read more
28 Jun 2023 16:18

GSK completes acquisition of chronic cough-focused Bellus Health

(Alliance News) - GSK PLC on Wednesday said it completed its acquisition of Quebec-based late-stage biopharmaceutical firm Bellus Health Inc for a total equity value of USD2.0 billion.

Read more
27 Jun 2023 08:21

GSK granted US FDA fast track for gonorrhoea vaccine

(Alliance News) - GSK PLC on Tuesday reported that the US Food & Drug Administration has granted its gonorrhoea investigational vaccine a "fast track" designation.

Read more
27 Jun 2023 08:07

GSK gonorrhoea vaccine gets FDA fast track designation

(Sharecast News) - GSK said on Tuesday that its investigational vaccine for sexually transmitted infection gonorrhoea has been granted a fast track designation by the US Food and Drug Administration.

Read more
27 Jun 2023 07:56

LONDON BRIEFING: Stocks called up; record profit for Telecom Plus

(Alliance News) - Stock prices in London were set to open higher on Tuesday, following a positive session for equities in Hong Kong and Shanghai.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.